Erratum to: J Neurooncol DOI 10.1007/s11060-009-0073-4
In the Absract of the original publication, the level numbers indicated for the Recommendations regarding SRS plus WBRT vs. WBRT alone were incorrect. The correct level numbers are shown below.
Recommendations
SRS plus WBRT vs. WBRT alone
Level 1 Single-dose SRS along with WBRT leads to significantly longer patient survival compared with WBRT alone for patients with single metastatic brain tumors who have a KPS ≥ 70.
Level 1 Single-dose SRS along with WBRT is superior in terms of local tumor control and maintaining functional status when compared to WBRT alone for patients with 1–4 metastatic brain tumors who have a KPS ≥ 70.
Level 2 Single-dose SRS along with WBRT may lead to significantly longer patient survival than WBRT alone for patients with 2–3 metastatic brain tumors.
Level 3 There is class III evidence demonstrating that single-dose SRS along with WBRT is superior to WBRT alone for improving patient survival for patients with single or multiple brain metastases and a KPS < 70.
Footnotes
The online version of the original article can be found under doi:10.1007/s11060-009-0073-4.